Goldman Sachs
VAXX

Goldman Sachs’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Goldman Sachs’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-95,575
Closed -$217K – 6165
2023
Q1 		$217K Buy
+95,575
New +$242K ﹤0.01% 5266
2022
Q2 		– Sell
-97,069
Closed -$417K – 6805
2022
Q1 		$417K Sell
97,069
-124,031
-56% -$685K ﹤0.01% 5451
2021
Q4 		$1.24M Buy
+221,100
New +$2.29M ﹤0.01% 4661

Other funds holding VAXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
SM
Scoggin Management New York $1.04B AUM 232.32% 1-Year Est. Return

Goldman Sachs's VAXX Position: Q2 2023 in Review

Goldman Sachs sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2023, closing a stake of 95,575 shares — an estimated $217K sold.

Goldman Sachs first reported a position in VAXX in Q4 2021 and held it in 3 quarters. The position peaked at $1.24M in Q4 2021. 49 funds tracked by Wall St. Rank hold VAXX as of Q2 2023.

  • Goldman Sachs reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 95,575 Vaxxinity, Inc. Class A Common Stock shares in Q2 2023, an estimated $217K.
  • Goldman Sachs first reported a position in Vaxxinity, Inc. Class A Common Stock in Q4 2021 and held it in 3 quarters.
  • Goldman Sachs's Vaxxinity, Inc. Class A Common Stock position peaked at $1.24M in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.